



Saige Brain

Assess and monitor neurodegenerative changes with quantitative and reference data.

FDA cleared | CE marked

Key benefits

- Leverage objective staging of atrophy and compare your patient's results to a reference population.
- Track atrophy and WMH progression and therapy response in patients with quantitative analysis.
- Enhance your communication using standardized, easy-to-understand reports to increase patient satisfaction.
- Read the results of the automated analysis when it fits your schedule.
- Seamless integration into your clinical workflow, on site or in the cloud.

Brain atrophy analysis

- Fully automatic brain segmentations and volumetry measurements including total brain volume, ICV, lobes, and hippocampus.
- All segmentations are sent to the PACS as DICOM secondary capture series.
- Reference centile curves combined with the volumetric measurements of your patient's brain structures.¹
- Cross-sectional and longitudinal analysis available to support single examinations as well as follow up exams.



User interface for WMH review


WMH analysis

- Cross-sectional and longitudinal analysis available to support single examinations and WMH progression tracking.
- Automatic WMH segmentation that can be corrected if needed.
- Fully automatic computation of volume changes and labeling of WMH as new, preexisting or disappearing.

¹ M. Ikram, A. van der Lugt, W. Niessen, P. Koudstaal, G. Krestin, A. Hofman, D. Bos and M. Vernooij, "The Rotterdam Scan Study: design update 2016 and main findings," European Journal of Epidemiology, 2015.


All results in clear standardized reports

Brain, hippocampus and brain lobes volumetry, volumetry change and percentiles



Reference curves that compare the patient's brain to a non-demented reference population

Total amount and volume of pre-existing, disappearing and new hyperintensities



Overview images